Tower Research Capital (TRC)’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-965	Closed	-$4K	–	6508
2022 Q4	$4K	Buy	965 +890	+1,187%	+$3.94K	﹤0.01%	5110
2022 Q3	$0	Sell	75 -647	-90%	-$3.6K	﹤0.01%	6683
2022 Q2	$4K	Sell	722 -970	-57%	-$5.47K	﹤0.01%	5293
2022 Q1	$12K	Sell	1,692 -2,269	-57%	-$22.2K	﹤0.01%	4116
2021 Q4	$53K	Buy	3,961 +2,223	+128%	+$36.8K	﹤0.01%	2722
2021 Q3	$40K	Buy	1,738 +1,482	+579%	+$44.1K	﹤0.01%	3135
2021 Q2	$11K	Sell	256 -191	-43%	-$10.6K	﹤0.01%	4350
2021 Q1	$32K	Buy	447 +21	+5%	+$1.49K	﹤0.01%	3531
2020 Q4	$18K	Buy	426 +244	+134%	+$10.9K	﹤0.01%	3948
2020 Q3	$7K	Sell	182 -47	-21%	-$2.43K	﹤0.01%	4263
2020 Q2	$14K	Buy	+229	New	+$21K	﹤0.01%	3880
2019 Q3	–	Sell	-149	Closed	-$21K	–	4633
2019 Q2	$21K	Buy	+149	New	+$26.2K	﹤0.01%	2158

Other funds holding ORTX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Kapitalo Investimentos Sao Paulo, Brazil $531M AUM 25.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Tower Research Capital (TRC)'s ORTX Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2023, closing a stake of 965 shares — an estimated $4K sold.

Tower Research Capital (TRC) first reported a position in ORTX in Q2 2019 and held it in 12 quarters. The position peaked at $53K in Q4 2021. 35 funds tracked by Wall St. Rank hold ORTX as of Q1 2023.

Tower Research Capital (TRC) reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 965 Orchard Therapeutics plc American Depositary Shares shares in Q1 2023, an estimated $4K.
Tower Research Capital (TRC) first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 12 quarters.
Tower Research Capital (TRC)'s Orchard Therapeutics plc American Depositary Shares position peaked at $53K in Q4 2021.
35 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.